Human Mucin-1/MUC-1 Isoform Y Protein
Catalog No: MUC1-HF002
- Species
- Human
- Expression System
- HEK293
- Tag
- an hFc (IgG1)
Product overview
Recombinant Human Mucin-1 Isoform Y Protein is expressed in HEK293 cells with an hFc (IgG1) tag at the C-terminus. It contains amino acid residues Ser24-Gly158 (UniProt accession: P15941-7).
Product Details
- Molecular Aliases
- MUC1/Y; MUC1; MUC-1; Mucin-1; Mucin1; CA 15-3; Episialin; H23AG; KL-6; PEMT; PUM; PEM; EMA; CD227;;CA15-3; KL6
- Protein Length
- Ser24-Gly158
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 41.38 kDa. Due to glycosylation, the protein migrates to 55-65 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 90% as determined by HPLC
- Endotoxin
- Less than 1 EU per μg by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Human Mucin-1 Isoform Y on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Human Mucin-1 Isoform Y is greater than 90% as determined by SEC-HPLC.
Background
MUC1, the transmembrane glycoprotein Mucin 1, is usually found to be overexpressed in a variety of epithelial cancers playing an important role in disease progression. MUC1 isoforms such as MUC1/Y, which lacks the entire variable number of tandem repeat region, are involved in oncogenic processes by enhancing tumour initiation. MUC1/Y is therefore considered a promising target for the identification and treatment of epithelial cancers.
References
- Khan H, Makwana V, Santos SND, Bonacossa de Almeida CE, Santos-Oliveira R, Missailidis S. Development, Characterization, and In Vivo Evaluation of a Novel Aptamer (Anti-MUC1/Y) for Breast Cancer Therapy. Pharmaceutics. 2021 Aug 11;13(8):1239. doi: 10.3390/pharmaceutics13081239. PMID: 34452200; PMCID: PMC8400696. Note: HPLC results always come from liquid protein, due to absorption peak interference of trehalose in lyophilized powder.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.